Article PDF
Avoid common mistakes on your manuscript.
References
Chakraborty, R, Muchtar, E, Kumar, S, et al. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplant. 2017;52;34–40.
Kumar, SK, Dispenzieri, A, Lacy, MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28;1122–8.
Kyle, RA, Child, JA, Anderson, K, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121;749–57.
Reeder, CB, Reece, DE, Kukreti, V, et al. Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009;23;1337.
Einsele, H, Liebisch, P, Langer, C, et al. Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial). Blood 2009;114;131.
Richardson, P, Weller, E, Lonial, S. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116;679–86.
Kumar, S, Flinn, I, Richardson, PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119;4375–82.
Mitsiades, N, Mitsiades, CS, Richardson, PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101;2377–80.
Ma, MH, Yang, HH, Parker, K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9; 1136–44.
Rajkumar, SV, Harousseau, J, Durie, B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117;4691–5.
Moreau, P, Attal, M, Hulin, C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019;394;29–38.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Andersen, K.T., Hinge, M., Szabo, A.G. et al. Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma. Clin Hematol Int 2, 35–39 (2020). https://doi.org/10.2991/chi.d.200116.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.200116.001